insulin icodec 700 U/mL PDS290
Sponsors
Novo Nordisk A/S
Conditions
Diabetes Type 2Type 2 Diabetes
Phase 3
A single arm study investigating the glycaemic control and safety of adding semaglutide to insulin icodec in participants with type 2 diabetes qualifying for treatment intensification.
CompletedCTIS2022-502717-28-00
Start: 2024-01-09End: 2025-05-23Target: 70Updated: 2025-05-23
A Study to Evaluate the Efficacy and Safety of Once-weekly Insulin Icodec when Switching from Daily Basal Insulins Compared to Once-daily Insulin Glargine U100 in Adults with Type 2 Diabetes
CompletedCTIS2023-506084-34-00
Start: 2024-04-12End: 2025-06-13Target: 145Updated: 2025-04-17